Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) — Market Cap & Net Worth
Market Cap & Net Worth: Kazia Therapeutics Ltd ADR (KZIA)
Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) has a market capitalization of $64.84 Million ($64.84 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20987 globally and #4738 in its home market, demonstrating a 18.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kazia Therapeutics Ltd ADR's stock price $11.82 by its total outstanding shares 11335991 (11.34 Million). Also see Kazia Therapeutics Ltd ADR balance sheet assets for a full breakdown of the balance sheet.
Kazia Therapeutics Ltd ADR Market Cap History: 2015 to 2026
Kazia Therapeutics Ltd ADR's market capitalization history from 2015 to 2026. Data shows change from $947.69 Million to $115.63 Million (-19.11% CAGR). Also see cash flow conversion of Kazia Therapeutics Ltd ADR for how efficiently the company converts equity into cash flow.
Index Memberships
Kazia Therapeutics Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #604 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2013 of 3165 |
Weight: Kazia Therapeutics Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kazia Therapeutics Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kazia Therapeutics Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check KZIA live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1859.64x
Kazia Therapeutics Ltd ADR's market cap is 1859.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $664.29 Million | $4.07 Million | -$12.06 Million | 163.18x | N/A |
| 2017 | $360.47 Million | $8.79 Million | -$10.67 Million | 41.02x | N/A |
| 2018 | $275.46 Million | $13.11K | -$6.04 Million | 21015.00x | N/A |
| 2019 | $491.98 Million | $1.56K | -$10.27 Million | 314365.50x | N/A |
| 2020 | $979.43 Million | $988.11K | -$12.47 Million | 991.22x | N/A |
| 2021 | $954.49 Million | $15.18 Million | -$8.42 Million | 62.87x | N/A |
| 2022 | $69.71 Million | $10.00K | -$25.01 Million | 6970.50x | N/A |
| 2023 | $49.82 Million | $555.00 | -$20.47 Million | 89768.79x | N/A |
| 2024 | $20.06 Million | $2.31 Million | -$26.78 Million | 8.69x | N/A |
| 2025 | $78.10 Million | $42.00K | -$20.70 Million | 1859.64x | N/A |
Competitor Companies of KZIA by Market Capitalization
Companies near Kazia Therapeutics Ltd ADR in the global market cap rankings as of September 18, 2026. Review Kazia Therapeutics Ltd ADR tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kazia Therapeutics Ltd ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Kazia Therapeutics Ltd ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, Kazia Therapeutics Ltd ADR's market cap moved from $947.69 Million to $ 115.63 Million, with a yearly change of -19.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $115.63 Million | +48.04% |
| 2025 | $78.10 Million | +289.27% |
| 2024 | $20.06 Million | -59.73% |
| 2023 | $49.82 Million | -28.52% |
| 2022 | $69.71 Million | -92.70% |
| 2021 | $954.49 Million | -2.55% |
| 2020 | $979.43 Million | +99.08% |
| 2019 | $491.98 Million | +78.60% |
| 2018 | $275.46 Million | -23.58% |
| 2017 | $360.47 Million | -45.74% |
| 2016 | $664.29 Million | -29.90% |
| 2015 | $947.69 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Kazia Therapeutics Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $64.84 Million USD |
| MoneyControl | $64.84 Million USD |
| MarketWatch | $64.84 Million USD |
| marketcap.company | $64.84 Million USD |
| Reuters | $64.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more